AU Patent

AU2018253950A1 — Combination therapy with an anti-CD25 antibody-drug conjugate

Assigned to ADC Therapeutics SA · Expires 2019-09-19 · 7y expired

What this patent protects

The present disclosure relates to combination therapies for the treatment of pathological conditions, such as cancer. In particular, the present disclosure relates to combination therapies comprising treatment with an Antibody Drug Conjugate (ADC) and a secondary agent.

USPTO Abstract

The present disclosure relates to combination therapies for the treatment of pathological conditions, such as cancer. In particular, the present disclosure relates to combination therapies comprising treatment with an Antibody Drug Conjugate (ADC) and a secondary agent.

Drugs covered by this patent

Patent Metadata

Patent number
AU2018253950A1
Jurisdiction
AU
Classification
—
Expires
2019-09-19
Drug substance claim
No
Drug product claim
No
Assignee
ADC Therapeutics SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.